Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175126 | 0.89 | EIF2AK4 (0.37) | EIF2AK4AURKAPDPK1AURKB | |
| SCHEMBL6169430 | 0.88 | EIF2AK4 (0.35) | EIF2AK4AURKAPDPK1AURKB | |
| SCHEMBL7501829 | 0.87 | SCN5A (0.38) | SCN5A | |
| SCHEMBL7506081 | 0.87 | SCN5A (0.38) | SCN5A | |
| SCHEMBL10208012 | 0.80 | PIM1 (0.36) | — | |
| SCHEMBL15256899 | 0.80 | PIM1 (0.36) | — | |
| SCHEMBL6169447 | 0.80 | EIF2AK4 (0.35) | EIF2AK4AURKAPDPK1AURKB | |
| SCHEMBL6170804 | 0.80 | SCN5A (0.39) | AURKBSCN5A | |
| SCHEMBL6170904 | 0.80 | SCN5A (0.39) | AURKBSCN5A | |
| Hydrochloric Acid SCHEMBL6475247 | 0.79 | SCN5A (0.38) | AURKBSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900224-B2 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1532137-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2004014893-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | EIF2AK4 1890/4885AURKA 2459/4885PDPK1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.